Literature DB >> 7861026

The type I interferon system is locally activated in psoriatic lesions.

P Schmid1, P Itin, D Cox, G K McMaster, M A Horisberger.   

Abstract

The expression of mRNAs encoding interferons (IFNs) and IFN-inducible proteins has been studied in psoriatic lesions and in noninvolved skin. The specific mRNAs have been detected by in situ hybridization using antisense RNAs. Signals for the expression of IFN-gamma mRNA have been found exclusively in cells of psoriatic lesions, and most likely represent a subpopulation of infiltrating leukocytes. Weak signals of IFN-alpha mRNA have been detected throughout the hyperkeratotic epidermis, although specific signals for IFN-beta mRNA expression were not detectable. The expression of two IFN-alpha-inducible gene products, namely the MxA protein and the 2'-5' oligoadenylate (2-5A) synthetase, have been studied as markers for the local activation of the IFN-alpha system. Expression of MxA mRNA and protein was observed in psoriatic keratinocytes, but not in normal appearing keratinocytes adjacent to the lesions. Similarly, 2-5A synthetase expression was markedly elevated in psoriatic keratinocytes. The results of the present study indicate that the IFN-alpha system is selectively activated in psoriatic lesions, although it remains silent in noninvolved skin. The implications of this finding are discussed within the boundaries of current understanding of the cytokine network.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7861026     DOI: 10.1089/jir.1994.14.229

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  15 in total

1.  Antimicrobial Peptide LL37 and MAVS Signaling Drive Interferon-β Production by Epidermal Keratinocytes during Skin Injury.

Authors:  Ling-Juan Zhang; George L Sen; Nicole L Ward; Andrew Johnston; Kimberly Chun; Yifang Chen; Christopher Adase; James A Sanford; Nina Gao; Melanie Chensee; Emi Sato; Yi Fritz; Jaymie Baliwag; Michael R Williams; Tissa Hata; Richard L Gallo
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

Review 2.  Antimicrobial peptides in the pathogenesis of psoriasis.

Authors:  Shin Morizane; Richard L Gallo
Journal:  J Dermatol       Date:  2012-03       Impact factor: 4.005

3.  Dual Inhibition of TNFR1 and IFNAR1 in Imiquimod-Induced Psoriasiform Skin Inflammation in Mice.

Authors:  Lynda Grine; Lien Dejager; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

Review 4.  The immunogenetics of Psoriasis: A comprehensive review.

Authors:  Jamie L Harden; James G Krueger; Anne M Bowcock
Journal:  J Autoimmun       Date:  2015-07-26       Impact factor: 7.094

Review 5.  Progress in understanding the immunopathogenesis of psoriasis.

Authors:  R K H Mak; C Hundhausen; F O Nestle
Journal:  Actas Dermosifiliogr       Date:  2009-12

Review 6.  Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases.

Authors:  Leanne M Johnson-Huang; N Scott McNutt; James G Krueger; Michelle A Lowes
Journal:  J Clin Immunol       Date:  2009-02-28       Impact factor: 8.317

Review 7.  The influence of interferon on healthy and diseased skin.

Authors:  Grace A Hile; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  Cytokine       Date:  2018-12-06       Impact factor: 3.861

Review 8.  Harnessing dendritic cells in inflammatory skin diseases.

Authors:  Chung-Ching Chu; Paola Di Meglio; Frank O Nestle
Journal:  Semin Immunol       Date:  2011-02-04       Impact factor: 11.130

9.  Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

Authors:  Frank O Nestle; Curdin Conrad; Adrian Tun-Kyi; Bernhard Homey; Michael Gombert; Onur Boyman; Günter Burg; Yong-Jun Liu; Michel Gilliet
Journal:  J Exp Med       Date:  2005-07-04       Impact factor: 14.307

Review 10.  The Role of Cutaneous Type I IFNs in Autoimmune and Autoinflammatory Diseases.

Authors:  Jessica L Turnier; J Michelle Kahlenberg
Journal:  J Immunol       Date:  2020-12-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.